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Abstract
Background: Fluoroquinolones or third generation cephalosporins are the drugs of choice for the
treatment of typhoid fever. Treatment failure with fluoroquinolones has been reported in Asia and
Europe. We report a case of ciprofloxacin treatment failure in typhoid fever in Cameroon.
Case presentation: A 29-year-old female patient with suspected typhoid fever from Kumba,
Cameroon, yielded growth of Salmonella enterica serovar Typhi in blood culture. The isolate was
resistant to nalidixic acid but sensitive to ciprofloxacin by disc diffusion test. However, the patient
did not respond to treatment with ciprofloxacin, although the isolate was apparently susceptible to
ciprofloxacin.
Conclusion: Treatment failure with ciprofloxacin in our case indicates the presence of nalidixic
acid resistant S. enterica serovar Typhi (NARST) with reduced susceptibility to ciprofloxacin in
Cameroon (Central Africa).
Case presentation
A 29-year-old woman from Kumba, Cameroon, was
admitted in January 2004 to St. John's Hospital and
Maternity, Kumba, with a five-day history of fever, emesis,
poorly localized abdominal discomfort, myalgias and
hepatosplenomegaly. Her total leukocyte count was 1.7 ×
109/l, (neutrophils 51%, lymphocytes 43%, monocytes
5%). Urinalysis was normal and thin and thick film exam-
inations of the peripheral blood were negative for
malaria. The patient also tested negative for HIV. A blood
Widal test however, showed a titre of 80 against "O"
(somatic) antigen and 160 against the "H" (flagella) anti-
gen of Salmonella enterica serovar Typhi (recommended
cut-off titre in our hospital: ≥  1:80 and ≥  1:160 for the "O"
and "H" antigens respectively). Blood culture grew Salmo-
nella enterica serovar Typhi. Two months prior to her ill-
ness, she had suffered from an attack of suspected typhoid
fever and had been treated with chloramphenicol 500 mg
every 6 hours for 14 days.
Antibiogram of the isolated S. enterica serovar Typhi was
performed by disc diffusion techniques as recommended
by NCCLS guidelines [1], Minimum inhibitory concentra-
tions (MIC) of nalidixic acid and ciprofloxacin were deter-
mined by agar dilution method [2]. The antibiotic discs
used included ampicillin 10 µg (Beecham), co-trimoxa-
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zole 1.25/23.75 µg (Roche), chloramphenicol 30 µg
(Antibioticos SA), ciprofloxacin 5 µg (Bayer), nalidixic
acid 30 µg (Sigma) and ceftriaxone 30 µg (Roche). The
isolate was found resistant to nalidixic acid, ampicillin,
co-trimoxazole and chloramphenicol, but susceptible to
ceftriaxone and ciprofloxacin by disc diffusion test. The
MICs of ciprofloxacin and nalidixic acid were 0.5 µg/ml
and 32.0 µg/ml respectively. The patient remained febrile
after 7 days of oral administration of 500 mg cipro-
floxacin every 12 hours. Thereafter, the patient was
administered 1 g ceftriaxone every 12 hours intrave-
nously, which rendered her afebrile within four days.
Treatment was continued for another 3 days. The patient
did not relapse on follow-up.
Conclusion
The emergence of multi-drug-resistant Salmonella enter-
ica serovar Typhi (MDRST) strains was first reported in the
80 s, in Asia. Sporadic cases of ciprofloxacin treatment
failure in typhoid fever have been reported in Europe and
more recently, in Asia [3,4]. Our report indicates that
MDRST and nalidixic acid resistant Salmonella enterica
serovar Typhi (NARST) strains are now appearing in Cam-
eroon, Central Africa. NARST have also been reported in
East Africa [5]. However, treatment failure with fluoroqui-
nolones in patients affected by the NARST strains in East
Africa has not been described, although several reports
suggest that the clinical response to fluoroquinolones in
patients infected with NARST may be inferior to the
response in those infected with nalidixic acid-susceptible
strains [[4-11], this report].
There may be single or multi-mutations in the quinolone-
resistance-determining region of either DNA gyrase (gyrA
or gyrB or both) or DNA topoimerase IV (parC and parE
or both) or both enzymes, which cause resistance of Sal-
monella enterica serovar Typhi strains to fluoroquinolone
[5,9]. Resistance may also be due to other mechanisms
such as decreased permeability and active efflux of the
antimicrobial agents. Previous studies have shown that
MDRST strains in East Africa were related to earlier drug-
susceptible isolates but were unrelated to MDRST isolates
from Asia. [10]. MDRST and NARST isolates in Central
African may be unrelated to those earlier reported in Asia,
Europe and east Africa [3-11].
Ceftriaxone is an alternative drug in cases of quinolone
resistant typhoid fever. However, there have been reports
of high-level resistance to ceftriaxone (MIC= 64 mg/l) in
both Salmonella enterica serovar Typhi and Paratyphi A
[3]. Third generation cephalosporins are also expensive (a
treatment course with parental Ceftriaxone is six times
more expensive compared to oral ciprofloxacin in Cam-
eroon), and regularly not available. The efficacy of azi-
thromycin, which was recently shown to be an effective
alternative treatment for uncomplicated enteric fever due
to MDRST, needs to be confirmed in patients with
typhoid fever due to a NARST strain [12]. Improved hygi-
enic conditions and effective surveillance methods to
monitor newly emerged MDRST and NARST strains in
Africa and other enteric fever endemic regions are of
utmost importance.
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